Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06000423 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT06000423 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 65 participants.
The verdict
NCT06000423, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text message service
Interventions
- OTHER Placebo
- DRUG Tranexamic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2025-08-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06000423
The ClinicalTrials.gov registry entry for NCT06000423 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06000423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06000423 about?
NCT06000423 is a clinical study titled "Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects". This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be...
What is the current status of trial NCT06000423?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2024-01-23. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT06000423?
The interventions under investigation include: Placebo (OTHER), Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT06000423?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.